A5076219640- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Genetic factors in colorectal cancer
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- CRISPR and Genetic Engineering
- Acupuncture Treatment Research Studies
- Immunodeficiency and Autoimmune Disorders
- Breast Cancer Treatment Studies
- Breast Implant and Reconstruction
- Brain Metastases and Treatment
- Melanoma and MAPK Pathways
- Liver Disease and Transplantation
National Cancer Institute
2016-2025
National Institutes of Health
2015-2025
Center for Cancer Research
2017-2025
Frederick National Laboratory for Cancer Research
2024
National Cancer Institute
2018
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2018
Bayer (France)
2017
University of Rochester
2017
AbbVie (United States)
2017
Seagen (Canada)
2017
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 been published. Patients that is chemotherapy refractory or relapsed after autologous stem-cell transplantation a grim prognosis, and new treatments for these patients are clearly needed. Chemotherapy administered before adoptive T-cell transfer has shown enhance the...
Adoptive T cell therapy (ACT) using ex vivo-expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact TIL phenotypes on clinical success TIL-ACT is currently unclear. Using high-dimensional analysis ACT products, we identified a memory-progenitor CD39-negative stem-like phenotype (CD39
Adoptive cell transfer, the infusion of large numbers activated autologous lymphocytes, can mediate objective tumor regression in a majority patients with metastatic melanoma (52 93; 56%). Addition and intensification total body irradiation (TBI) to preparative lymphodepleting chemotherapy regimen sequential trials improved partial complete response (CR) rates. Here, we evaluated importance adding TBI adoptive transfer tumor-infiltrating lymphocytes (TIL) randomized fashion.A 101 melanoma,...
BACKGROUND. Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis and overexpressed antigens thus far resulted in little clinical benefit. Studies conducted by multiple groups demonstrated that T cells recognizing neoantigens are present most cancers offer a specific highly immunogenic target for personalized vaccination.
A deletion variant of epidermal growth factor receptor (EGFRvIII) is a known driver mutation in subset primary and secondary glioblastoma multiforme. Adoptive transfer genetically modified chimeric antigen (CAR) lymphocytes has demonstrated efficacy hematologic malignancies but still early development for solid cancers. The surface expression the truncated extracellular ligand domain created by EGFRvIII makes it an attractive target CAR-based cancer treatment. Patients with recurrent...
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures CD8
Abstract Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients common epithelial cancers. This raises the question whether these cancers harbor T lymphocytes that recognize mutant proteins expressed by autologous may represent ideal targets for immunotherapy. Using high-throughput immunologic screening gene products identified via whole-exome sequencing, we neoantigen-reactive tumor-infiltrating (TIL) from 62 75 (83%)...
PURPOSE Anti-CD19 chimeric antigen receptors (CARs) are artificial fusion proteins that cause CD19-specific T-cell activation. Durability of remissions and incidence long-term adverse events critical factors determining the utility anti-CD19 CAR therapy, but follow-up patients treated with T cells is limited. This work provides longest in remission after therapy. METHODS Between 2009 2015, we administered 46 treatments to 43 (ClinicalTrials.gov identifier: NCT00924326 ). Patients had...
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC) class I–restricted T-cell receptors (TCRs) or chimeric antigen to modify CD8 + bulk treatment. Here, we evaluated the safety and efficacy an adoptive CD4 therapy using MHC II–restricted, HLA-DPB1*0401–restricted TCR recognized cancer germline antigen, MAGE-A3 (melanoma-associated...
PURPOSE Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in and explores therapeutic efficacy a pilot trial mutation-reactive tumor-infiltrating lymphocytes (TILs) patients metastatic disease. PATIENTS AND METHODS Forty-two mBrCa refractory previous lines treatment underwent surgical resection lesion(s), isolation TIL cultures, identification exomic...
Abstract Purpose: Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TIL) can mediate durable responses in patients with metastatic melanoma. This retrospective analysis provides long-term follow-up and describes the effect prior therapy on outcomes after ACT-TIL. Patients Methods: melanoma underwent surgical resection a tumor for generation TILs were treated lymphodepleting preparative regimen followed by adoptive intravenous IL2. Clinical characteristics enrolled...
Background Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often rare and exhausted, ex vivo expansion further reduce their frequencies. This complicates the identification T-cell receptors (TCRs) development TIL products with high reactivity patient treatment. Methods We tested whether could be in vitro...
Background The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases epithelial cancer. For the treatment latter, selecting cells for therapy typically involves laborious screening TIL recognition autologous tumor-specific mutations, detected through next-generation sequencing freshly resected tumors. Our study explored feasibility using archived formalin-fixed, paraffin-embedded (FFPE) primary...
Summary: Ideal antiepileptic drugs (AEDs) are designed to stop seizures with limited central nervous system (CNS) side effects. However, CNS‐related treatment‐emergent adverse events (TEAEs) often occur in patients receiving AEDs. Topiramate (TPM) is an AED proven be safe and effective as adjunctive treatment for epilepsy partial seizures. Double‐blind, placebo‐controlled, multicenter trials demonstrated potential effects on cognition. The P.A.D.S. (post‐marketing drug survey) group, a...
Adoptive cell transfer of tumor-infiltrating lymphocytes (TILs) can mediate objective tumor regression in 49% to 72% patients with many long-term durable responses. To undergo treatment a patient must have (1) resectable from which (2) TIL be generated that (3) exhibit tumor-specific reactivity. From July 2002 2007, 787 tumors 402 were processed for possible use the generation TIL, leading eventual 107 (27%). Viable TILs 376 (94%), and active, specific identified 269 (67%). Patient...